Sensory-Evoked Cortical Gamma Oscillation: Impact on Visual Processing and Cognitive Function in Patients With Alzheimer's Disease

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of the study is to investigate the efficacy of cortical gamma oscillation on visual sensory processing and cognitive function in Alzheimer's Disease (AD) patients by combining a therapeutic sensory stimulation device capable of evoking 40-Hz gamma oscillation via non-invasive visual and auditory stimulation with pre-established markers of cortical network activity, i.e., electroencephalography (EEG) and event-related potentials (ERP), to evaluate the applicability of the 40-Hz multimodel sensory stimulation as a novel therapeutic approach for treatment of AD patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 60
Healthy Volunteers: f
View:

• Individuals ages 60 and older with established diagnosis of Alzheimer's Disease as defined by the current consensus criteria for AD (Albert et al, 2011, Jack et al, 2011; McKhann et al, 2011)

• Fluent and literate in English language

• Able to consent for themselves based upon the MacArthur Competence Assessment Tool for Clinical Research

• Patients with a pre-existing positive A(beta)-PET and/or CSF tau/A(beta) markers or willingness to undergo a Lumbar Puncture (LP) with these results

Locations
United States
Tennessee
University of Tennessee Medical Center
RECRUITING
Knoxville
Contact Information
Primary
Roberto Fernandez-Romero, MD
rfernandez@utmck.edu
865-305-7242
Backup
Kyle Dean
kdean1@utmck.edu
865-305-2273
Time Frame
Start Date: 2022-07-01
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 20
Treatments
Experimental: AD Patients
Patients with Alzheimer's Disease, as verified by positive A(beta)-PET and/or CSF tau/A(beta) biomarkers, who will receive one hour daily gamma frequency sensory stimulation from the investigational device for an 8 week period.
Related Therapeutic Areas
Sponsors
Leads: University of Tennessee Medical Center

This content was sourced from clinicaltrials.gov